Mobitil 15mg/1.5ml 3 ampoules

Tradename

Mobitil

Mobitil

Properties

Meloxicam is a non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory and antipyretic effects. The mechanism of action is associated with inhibition of prostaglandin synthesis as a result of selective suppression of the enzymatic activity of cyclooxygenase-2 (COX-2), which is involved in the biosynthesis of prostaglandins in the area of inflammation. When used in high doses, long-term use and individual characteristics of the organism, COX-2 selectivity decreases. Suppresses the synthesis of prostaglandins in the area of inflammation to a greater extent than in the gastric mucosa or kidneys, which is associated with a relatively selective inhibition of COX-2. Rarely causes erosive and ulcerative changes in the gastrointestinal tract. To a lesser extent, meloxicam acts on cyclooxygenase-1 (COX-1), which is involved in the synthesis of prostaglandins that protect the gastrointestinal mucosa and are involved in the regulation of blood flow in the kidneys.

Indications

— symptomatic treatment of osteoarthritis;

— symptomatic treatment of rheumatoid arthritis;

— symptomatic treatment of ankylosing spondylitis (Bekhterev’s disease), other degenerative diseases of the joints, accompanied by pain.

Dosage and administration

Set individually, depending on the intensity of pain and the severity of the inflammatory process. Assign i / m at a dose of 7.5 mg or 15 mg 1 time / day.

Contraindications

Hypersensitivity to meloxicam; hypersensitivity (including to other NSAIDs); complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose or paranasal sinuses, angioedema or urticaria caused by intolerance to acetylsalicylic acid or other NSAIDs due to the existing likelihood of cross-sensitivity (including history); erosive and ulcerative lesions of the stomach and duodenum in the acute stage or recently transferred; inflammatory bowel disease (Crohn’s disease or ulcerative colitis in the acute stage); severe liver and heart failure; severe renal failure (if hemodialysis is not performed, CC <30 ml / min, as well as with confirmed hyperkalemia); active liver disease; active gastrointestinal bleeding, recent cerebrovascular bleeding or established diagnosis of diseases of the blood coagulation system; concomitant therapy with anticoagulants, tk. there is a risk of intramuscular hematoma formation; therapy of perioperative pain during coronary artery bypass surgery; pregnancy; lactation period (breastfeeding); children and adolescents up to 13 years of age.

Precautionary measures:

Influence on the ability to drive vehicles and mechanisms:

Side effects

From the side of the nervous system: often — headache; infrequently — dizziness, drowsiness.

From the sense organs: infrequently — vertigo; rarely — conjunctivitis, visual disturbances, including blurred vision, tinnitus.

From the digestive system: often — abdominal pain, dyspepsia, diarrhea, nausea, vomiting.